摘要目的：探讨尤瑞克林治疗急性缺血性卒中的临床疗效及其对同型半胱氨酸水平的影响。方法选取2013年1月至2015年1月太原市中心医院收治的急性缺血性卒中患者140例，将其随机分为观察组和对照组，各70例。两组患者均接受相同的常规治疗措施，包括脱水、降低颅内压、抗血小板聚集、降血压、血糖、血脂，改善脑循环以及营养脑神经等药物治疗；观察组在此基础上加用尤瑞克林，剂量为0.15 PNA U/d，两组患者均持续治疗2周。对比分析两组患者治疗前后的神经功能缺损程度、日常生活活动能力、治疗总有效率和不良反应发生率，同时测定所有患者治疗前后的同型半胱氨酸水平。结果两组患者经过治疗后，其神经功能缺损程度和日常生活活动能力均较治疗前显著改善（P<0.05）；与对照组相比，观察组改善的程度更为显著（P<0.05）；观察组的治疗总有效率高达87.1%，明显高于对照组的47.1%（P<0.01），与对照组相比，观察组的不良反应发生率无明显增加（P>0.05）。经过治疗后两组患者的血浆同型半胱氨酸水平均显著下降（P<0.05），且观察组降低程度更明显（P<0.05）。结论尤瑞克林治疗急性缺血性卒中能有效改善患者的神经功能，降低同型半胱氨酸水平，提高治疗总有效率，安全性好，值得临床推广应用。

abstractsObjective To investigate the clinical effect of Urinary kallidinogenase on the treatment of acute cerebral stroke and its effect on homocysteine levels. Methods 140 patients with acute cerebral stroke in Taiyuan Central Hospital from January 2013 to January 2015 were randomly divided into observation group and the control group, each group contains 70 cases. Both groups received routine treatment, including dehydration, reducing intracranial pressure, antiplatelet, anticoagulant drugs, controlling blood pressure/glucose/LDL-C, improving cerebral circulation and proving brain nutrition. In addition, the observation group was administered intravenous drip once daily with 0.15 PNA Urinary kallidinogenase. Both groups were treated for 2 weeks. Compare the neurologic function deficits and ability of daily life of patients with acute cerebral stroke and the total clinical effect and safety in both groups before and after treatment. In the mean time, the plasma homocysteine levels were also measured before and after the treatment in both groups. Results The degree of neurological function impairment and daily life activity were significantly improved compared with those before treatment in both groups, the difference was statistically significant (P<0.05);The degree of improvement in the observation group was significantly higher than that in the control group (P<0.05);The total effective rate of observation group was 87.1%,which was significantly higher than that of the control group (P<0.01). The plasma homocysteine levesl in the two groups were significantly decreased after treatment, and the observation group was significantly different from the control group (P<0.05). Conclusion Urinary kallidinogenase can effectively improve the neurological function and reduce the level. of homocysteine in patients with acute cerebral stroke. It can improve the treatment efficiency and safety in treating acute cerebral stroke, it is worthy of popularization and application in clinic.